Work

The Immunotherapy Revolution in Genitourinary Malignancies

Year: 2020

Type: article

Abstract: Immune checkpoint inhibitor (ICI) therapy and therapeutic cancer vaccines have continued to demonstrate survival benefit and durable clinical response in patients with renal cell cancer, prostate cancer and bladder cancer, with limited responses in testicular cancer. The role of immunotherapy in combination with chemotherapy or other targeted therapies in the neo-adjuvant, adjuvant and metastatic setting is actively being explored. We describe the current immunotherapy-related treatment modalities approved for genitourinary cancers, focusing on immune checkpoint inhibitors, vaccines and other modalities, and highlight ongoing studies involving immunotherapy in these cancer types.

Source: Immunotherapy

DOI: 10.2217/imt-2020-0054

Authors: Shruti U Gandhy, Ravi A Madan, Jeanny B Aragon-Ching

Institutions: National Institutes of Health, National Cancer Institute, Inova Fairfax Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W3037565490

FWCI: 0.882

Cites: 84

Cited by: 16

Related to: 10